肌萎缩侧索硬化症治疗市场 - 全球产业规模、份额、趋势、机会和预测，按治疗、按类型、按配销通路、按地区和竞争细分，2019-2029F

2023年全球肌萎缩侧索硬化症治疗市值为6.8901亿美元，预计2029年将达到9.6313亿美元，预测期内复合年增长率为5.71%。

市场概况
预测期	2025-2029
2023 年市场规模	68901万美元
2029 年市场规模	96313万美元
2024-2029 年复合年增长率	5.71%
成长最快的细分市场	干细胞治疗
最大的市场	北美洲

由于对解决这种进行性神经退化性疾病的创新疗法的需求不断增长，全球肌萎缩侧索硬化症 (ALS) 治疗市场正在迅速发展。 ALS 主要影响大脑和脊髓的神经细胞，导致肌肉控制和活动能力丧失。随着全球盛行率的不断增加，疾病缓解疗法和改进的诊断方法的研发投资不断增加，支撑了这个市场。製药公司正致力于开发先进的治疗方法，包括基因疗法、干细胞疗法和神经保护药物，旨在减缓疾病进展并改善患者的治疗结果。扩大医疗保健服务的覆盖范围和诊断技术的进步也有助于早期检测和更好的疾病管理，从而促进市场成长。

ALS 治疗市场的主要驱动力包括人们对神经退化性疾病的认识不断增强，以及针对 ALS 特定途径的精准医学的发展。倡导团体和医疗保健组织在提高公众对 ALS 症状和治疗的了解方面发挥着至关重要的作用，从而提高诊断率和更积极主动的管理。学术机构和生技公司之间的合作正在加速新药和疗法的发现。使用生物标记进行个人化治疗和标靶药物输送系统等创新为进一步扩大市场提供了有希望的机会。

儘管取得了这些进展，ALS 治疗市场仍面临重大挑战。与药物开发相关的高成本、严格的监管要求以及有效治疗方法的有限性仍然是主要障碍。此外，ALS 作为一种疾病的复杂性及其多种潜在机制，为开发通用疗法带来了困难。在许多地区，获得先进护理和治疗选择的机会仍然有限，这进一步阻碍了市场的成长。透过增加资金、研究合作和技术进步来克服这些挑战对于确保 ALS 治疗领域的持续进展至关重要。

主要市场驱动因素

ALS 和神经退化性疾病的盛行率不断上升

治疗方法的进步

专注个人化医疗

主要市场挑战

开发和治疗成本高

与治疗相关的副作用

主要市场趋势

不断增加的临床试验和药物开发

个人化和标靶治疗的成长

细分市场洞察

治疗见解

类型洞察

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球肌萎缩侧索硬化症治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依治疗（药物 [利鲁唑、依达拉奉、其他]、干细胞疗法、其他）
  • 按类型（散发性 ALS、家族性 ALS）
  • 按配销通路（医院药房、零售药房、其他）
  • 按公司划分 (2023)
  • 按地区
• 市场地图

第 6 章：北美肌萎缩侧索硬化症治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按治疗
  • 按类型
  • 按配销通路
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第 7 章：欧洲肌萎缩侧索硬化症治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按治疗
  • 按类型
  • 按配销通路
  • 按国家/地区
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第 8 章：亚太地区肌萎缩侧索硬化症治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按治疗
  • 按类型
  • 按配销通路
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第 9 章：南美洲肌萎缩侧索硬化症治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按治疗
  • 按类型
  • 按配销通路
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲肌萎缩侧索硬化症治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按治疗
  • 按类型
  • 按配销通路
  • 按国家/地区
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新动态

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第14章：竞争格局

• Mitsubishi Tanabe Pharma Corporation
• Biogen Inc.
• Brainstorm Cell Therapeutics Ltd.
• Amylyx Pharmaceuticals, Inc.
• Ionis Pharmaceuticals, Inc.
• Sanofi SA
• Otsuka Pharmaceutical Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Orion Corporation
• AB Science

第 15 章：策略建议

第16章调查会社について・免责事项

Global Amyotrophic Lateral Sclerosis Therapeutics Market was valued at USD 689.01 Million in 2023 and is expected to reach USD 963.13 Million by 2029 with a CAGR of 5.71% during the forecast period.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 689.01 Million
Market Size 2029	USD 963.13 Million
CAGR 2024-2029	5.71%
Fastest Growing Segment	Stem Cell Therapy
Largest Market	North America

The Global Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market is evolving rapidly due to rising demand for innovative treatments addressing this progressive neurodegenerative disease. ALS primarily affects nerve cells in the brain and spinal cord, leading to loss of muscle control and mobility. With an increasing global prevalence, the market is underpinned by growing investments in research and development for disease-modifying therapies and improved diagnostic methods. Pharmaceutical companies are focusing on developing advanced therapeutic approaches, including gene therapy, stem cell therapy, and neuroprotective drugs, which aim to slow disease progression and improve patient outcomes. Expanding access to healthcare services and advancements in diagnostic technology are also contributing to earlier detection and better disease management, boosting market growth.

Key drivers for the ALS therapeutics market include the growing awareness of neurodegenerative diseases and the development of precision medicine targeting ALS-specific pathways. Advocacy groups and healthcare organizations are playing a vital role in increasing public understanding of ALS symptoms and treatments, leading to a higher diagnosis rate and more proactive management. Collaborative efforts between academic institutions and biotech firms are accelerating the discovery of new drugs and therapies. Innovations such as the use of biomarkers for personalized treatment and targeted drug delivery systems are providing promising opportunities for further expansion of the market.

Despite this progress, the ALS therapeutics market faces significant challenges. High costs associated with drug development, stringent regulatory requirements, and the limited availability of effective treatments remain major hurdles. Additionally, the complexity of ALS as a disease, with its diverse underlying mechanisms, poses difficulties in developing universal therapies. Access to advanced care and treatment options is still limited in many regions, further impeding the market's growth. Overcoming these challenges through increased funding, research collaborations, and technological advancements will be critical in ensuring sustained progress in the ALS therapeutics landscape.

Key Market Drivers

Rising Prevalence of ALS and Neurodegenerative Disorders

The rising prevalence of amyotrophic lateral sclerosis (ALS) and neurodegenerative disorders is a critical driver for the market's growth. ALS, a progressive disorder affecting nerve cells in the brain and spinal cord, impacts motor function and leads to muscle degeneration. For instance, as per the National Institutes of Health (NIH), the global prevalence of amyotrophic lateral sclerosis (ALS) is projected to rise significantly, increasing from 222,801 cases in 2015 to 376,674 cases by 2040, marking a 69% growth. The most substantial regional growth is anticipated in Africa, with a rise of 116%, followed by Asia at 81% and South America at 73%.

In addition, as per Centers for Disease Control and Prevention (CDC) 2023 report, the prevalence of amyotrophic lateral sclerosis (ALS) in the United States stands at approximately 9.1 cases per 100,000 individuals.

Studies also show that aging is a major risk factor for ALS, aligning with projections that the elderly population will double by 2050 according to WHO data. This demographic trend is coupled with improved diagnostic capabilities, allowing for earlier and more accurate detection of ALS and similar conditions.

Increased funding and collaboration among stakeholders in healthcare are further propelling the development of innovative solutions. With neurodegenerative disorders becoming a growing health burden, the focus on discovering effective treatments continues to shape advancements in the ALS therapeutics market.

Advancements in Therapeutic Approaches

Advancements in therapeutic approaches are one of the key drivers of the growth of the Global Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market. Traditional treatments for ALS have focused primarily on managing symptoms and providing palliative care, but recent breakthroughs in the development of disease-modifying therapies are revolutionizing the landscape. Gene therapies, which aim to address genetic mutations directly responsible for ALS, are showing promising results in clinical trials. A notable example is the development of antisense oligonucleotides (ASOs), such as nusinersen (Spinraza), which targets genetic mutations that lead to ALS and is designed to slow the progression of the disease.

Stem cell therapies are also gaining attention as a potential solution to repair damaged neurons and regenerate lost motor function. These therapies aim to replace or protect motor neurons affected by ALS, offering hope for long-term survival and improved quality of life for patients. In addition to gene and stem cell therapies, other neuroprotective treatments that target oxidative stress, mitochondrial dysfunction, and neuroinflammation are being researched, aiming to slow disease progression.

These innovations are being accelerated by collaboration between biotechnology companies, research institutions, and patient advocacy groups, which have increased funding and support for ALS research. As these new therapies progress through clinical trials and regulatory approvals, they are expected to offer more effective treatment options and contribute to the market's rapid growth.

Focus on Personalized Medicine

The focus on personalized medicine has become a significant driver for the Global Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market. Personalized medicine leverages genetic profiling and patient-specific biomarkers to design targeted treatments that are more effective and cause fewer side effects. In ALS, where patients experience varied progression and symptoms, a one-size-fits-all approach is often inadequate. Personalized treatments allow for more tailored therapies, addressing the unique genetic factors contributing to ALS in each patient. For instance, gene therapies that target specific genetic mutations such as those found in familial ALS provide more precise treatment options compared to traditional methods. This precision approach has led to the development of therapies that can slow disease progression and improve outcomes for patients.

The rise in genomic medicine and advancements in diagnostic tools have facilitated the shift toward personalized ALS treatments. With the identification of biomarkers that indicate disease progression, clinicians can tailor treatment plans to individual needs, improving both the quality of life and survival rates of ALS patients. This move towards personalized therapies has garnered support from the scientific community and regulatory bodies, accelerating the approval of treatments. As personalized medicine continues to gain traction, it has the potential to revolutionize the ALS treatment landscape, offering hope for more effective management of the disease.

Key Market Challenges

High Development and Treatment Costs

The high development and treatment costs are significant barriers to the growth of the Global Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market. ALS is a complex neurodegenerative disease, and developing treatments for it involves substantial financial investments. From the discovery phase to clinical trials and final product commercialization, the process is both lengthy and costly. Research into ALS treatments often requires the development of novel drug delivery systems, genetic therapies, and neuroprotective agents, all of which demand advanced technology, sophisticated infrastructure, and highly specialized expertise. The expense of these efforts significantly drives up the costs for developing new therapies.

The clinical trial process is particularly expensive. ALS, being a rare disease, has a limited patient pool, which complicates the recruitment for clinical trials. The small number of patients means that trials are often smaller in scale, which makes it difficult to obtain statistically significant results. This issue increases both the duration and cost of trials. Additionally, due to the rarity of ALS, finding patients who fit the specific trial criteria further exacerbates recruitment challenges. As a result, pharmaceutical companies often face higher costs per participant, extending the time required to gain regulatory approval for new treatments.

Once therapies reach the market, the cost of treatment remains high. Due to the high cost of research and development, manufacturers often price new ALS drugs at a premium, making them inaccessible to many patients. While some insurance plans may cover these treatments, access can still be limited, particularly in lower-income regions. The disparity in access to care and therapies further compounds the challenges faced by patients with ALS. This issue leads to healthcare inequities and slows the broader adoption of innovative treatments.

Side effects associated with treatment

One of the significant challenges in the Global Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market is the side effects associated with available treatments. Many current therapies for ALS, including riluzole and edaravone, are primarily aimed at slowing the disease's progression rather than offering a cure, and their efficacy can be limited. These treatments are often associated with various side effects that can hinder their use in patients. For instance, riluzole has been linked to liver toxicity, gastrointestinal issues, and fatigue, while edaravone has shown side effects such as difficulty breathing, skin irritation, and infusion reactions. The presence of such side effects may discourage patients from adhering to their treatment regimen, leading to suboptimal therapeutic outcomes.

The nature of ALS as a complex and progressive disease further complicates treatment, as patients often experience a combination of symptoms that can exacerbate side effects. For example, patients with compromised respiratory function may struggle with medications that impact breathing, while those with weakened muscles may find it difficult to tolerate treatments that require intravenous administration or other complex delivery methods. The combination of ALS-related symptoms and treatment side effects increases the burden on patients and their caregivers, which may affect their quality of life.

In addition to the direct side effects, the lack of long-term safety data for some ALS drugs adds another layer of complexity. Because many of these treatments are still in the clinical or early approval stages, the long-term consequences and side effect profiles are not fully understood, creating uncertainty for both physicians and patients. As ALS is a progressive disease, patients often experience prolonged periods of treatment, which means the cumulative effects of side effects over time can become more pronounced, further complicating treatment decisions.

Key Market Trends

Rising Clinical Trials and Drug Developments

The global Amyotrophic Lateral Sclerosis (ALS) therapeutics market is experiencing significant momentum, particularly driven by the surge in clinical trials and drug development efforts aimed at addressing the unmet needs of ALS patients. With the increasing focus on understanding ALS's molecular underpinnings, researchers and pharmaceutical companies are dedicating resources to creating targeted therapies that go beyond symptom management. Recent advancements in gene therapy, antisense oligonucleotides, and small molecules are central to this shift. Clinical trials for new ALS drugs have accelerated, with studies targeting specific mutations like SOD1, C9orf72, and FUS, which are implicated in familial ALS. For instance, Ionis Pharmaceuticals' antisense oligonucleotide, targeting SOD1, has shown promise in early trials, demonstrating the potential for gene-specific therapies that could slow disease progression. The success of such treatments marks a new phase in ALS research, where rather than just managing symptoms, therapies aim to modify the course of the disease. The FDA's recent approval of drugs like Radicava and its fast-tracking of ALS-related therapies further illustrates the commitment to bringing effective treatments to market quickly. Moreover, the increasing investment in clinical trials is a positive indicator for the future of ALS therapeutics, with new drugs and treatment strategies being explored across various phases of clinical development. These innovations are expected to offer hope for patients, potentially changing the ALS therapeutic landscape by providing long-term disease-modifying options.

This trend toward growing clinical trials and drug developments is crucial to the evolution of ALS treatment options. With an increasing number of trials exploring novel compounds, therapeutic classes, and combination therapies, there is optimism that these efforts will yield breakthroughs. ALS, a progressive and fatal neurodegenerative disease, has long had limited treatment options, making the success of clinical trials an exciting prospect for patients and the healthcare community. In the coming years, the landscape of ALS therapeutics could shift dramatically, driven by the introduction of more targeted and personalized treatment options. These developments highlight the importance of continued investment in ALS research, aiming to improve the quality of life for patients and extend survival rates.

Growth in Personalized and Targeted Therapies

The trend of growth in personalized and targeted therapies is transforming the global Amyotrophic Lateral Sclerosis (ALS) therapeutics market. ALS is a complex and progressive neurodegenerative disease that manifests in various forms, leading to the development of therapies specifically designed for distinct genetic and molecular subtypes of the disease. Personalized medicine, which tailors treatment based on an individual's genetic makeup, is gaining prominence as it offers the potential for more effective and precise treatments. This approach is particularly important in ALS, where the disease may be driven by specific genetic mutations, such as those seen in familial ALS (FALS).

Targeted therapies are being developed to address the underlying causes of ALS at the molecular level. For instance, treatments like antisense oligonucleotides (ASOs) are being researched to target and alter the genetic instructions of mutated genes that cause ALS. These therapies aim to slow the progression of the disease and extend patient survival by targeting specific genes such as C9orf72, SOD1, and TDP-43, which are implicated in ALS. By focusing on the genetic mutations responsible for ALS, targeted therapies hold promise in improving outcomes for patients who otherwise have limited treatment options.

This shift towards personalized medicine and targeted therapies is spurred by advances in genomic research and technology, as well as the growing understanding of ALS at the molecular level. The approval of treatments like nusinersen (Spinraza) and radicava (edaravone), both of which focus on slowing disease progression, represents a milestone in the evolution of ALS treatment. These therapies are designed with specific molecular targets in mind, showcasing the growing trend toward individualized treatment plans.

Moreover, collaborations between biotechnology companies and research institutions are accelerating the development of new targeted therapies for ALS. Clinical trials focusing on gene therapies and other personalized treatment modalities are on the rise, signaling a promising future for the ALS therapeutics market. As these treatments become more refined and accessible, they are expected to improve the quality of life for ALS patients and extend their survival, driving the market forward.

Segmental Insights

Treatment Insights

In 2023, based on the treatment, the medication segment is dominating the Global Amyotrophic Lateral Sclerosis Therapeutics Market. This is due to the increasing development and approval of drug therapies aimed at slowing the progression of the disease. ALS is a devastating neurodegenerative condition with no known cure, making effective drug treatments essential for managing symptoms and prolonging survival. Recent advancements in medication for ALS, such as edaravone (Radicava) and nusinersen (Spinraza), have significantly contributed to the growth of this segment. These drugs, designed to address specific molecular and genetic factors involved in ALS, offer hope by slowing disease progression, enhancing patient quality of life, and extending survival.

Furthermore, the growing focus on molecular and genetic research has led to the development of targeted therapies, including gene therapy, which continues to make strides in clinical trials. These therapies are designed to address the root causes of ALS, which have spurred an increasing demand for innovative medications. With limited treatment options, ALS medications are often the primary therapeutic approach, making this segment a critical driver in the market's growth. As a result, the ALS medication segment is expected to maintain its dominant position in the global market throughout the forecast period.

Type Insights

Based on the type, the Sporadic ALS segment dominated the Global Amyotrophic Lateral Sclerosis Therapeutics Market. This is due to the higher incidence and prevalence of this form compared to familial ALS. Sporadic ALS accounts for approximately 90-95% of all ALS cases worldwide. It occurs without a clear genetic link and typically manifests in individuals aged 40-70, with men being more commonly affected. The lack of a known genetic cause makes treatment development challenging but also emphasizes the need for targeted therapies that focus on slowing disease progression in a broader patient population.

This widespread occurrence of sporadic ALS contributes to its market dominance, as pharmaceutical companies are heavily focused on finding effective treatments for this type, given its higher patient volume. Moreover, the research and clinical trials related to sporadic ALS have advanced significantly, with several drugs either in development or already approved for treating symptoms and slowing disease progression, such as edaravone (Radicava) and riluzole. These factors drive both research investment and market growth.

Due to the larger patient base, healthcare providers are increasingly investing in ALS therapeutics that specifically address sporadic cases. As a result, there is greater emphasis on therapeutic options that can be used across a wide patient demographic, including drugs aimed at reducing oxidative stress, inflammation, and neurodegeneration-all of which are key factors in sporadic ALS pathophysiology. The market is expected to see further growth as clinical research continues to refine treatments for sporadic ALS, providing new opportunities to improve patient outcomes and extend survival rates.

Regional Insights

In 2023, North America emerged as the dominant region in the Global Amyotrophic Lateral Sclerosis Therapeutics Market, holding the largest market share. This dominance can be attributed to several key factors, including advanced healthcare infrastructure, a strong focus on ALS research, and significant investment in innovative therapeutics. The United States, in particular, stands at the forefront of the ALS therapeutic market due to its established biotechnology and pharmaceutical industries, which are actively involved in the development of cutting-edge treatments. The U.S. government, through organizations like the National Institutes of Health (NIH), has significantly funded ALS research, spurring the development of novel therapies.

The approval of new ALS treatments such as Radicava (edaravone) and Nusinersen (Spinraza) in North America has further strengthened the region's market position. The U.S. Food and Drug Administration (FDA) has accelerated the approval of ALS drugs, facilitating quicker access to promising therapies. As a result, there has been a steady increase in treatment availability, leading to better disease management and an improvement in patients' quality of life.

In addition to regulatory advancements, the region benefits from a growing awareness of ALS, supported by advocacy groups like the ALS Association. These organizations have played a critical role in raising public awareness and driving research funding. Furthermore, North America is home to a large number of clinical trials for ALS therapeutics, providing a solid foundation for the development and commercialization of new treatments.

Key Market Players

• Mitsubishi Tanabe Pharma Corporation
• Biogen Inc.
• Brainstorm Cell Therapeutics Ltd.
• Amylyx Pharmaceuticals, Inc.
• Ionis Pharmaceuticals, Inc.
• Sanofi S.A.
• Otsuka Pharmaceutical Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Orion Corporation
• AB Science

Report Scope:

In this report, the Global Amyotrophic Lateral Sclerosis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Amyotrophic Lateral Sclerosis Therapeutics Market, By Treatment:

• Medication
  • Riluzole
  • Edaravone
  • Others
• Stem Cell Therapy
• Others

Amyotrophic Lateral Sclerosis Therapeutics Market, By Type:

• Sporadic ALS
• Familial ALS

Amyotrophic Lateral Sclerosis Therapeutics Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Others

Amyotrophic Lateral Sclerosis Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Amyotrophic Lateral Sclerosis Therapeutics Market.

Available Customizations:

Global Amyotrophic Lateral Sclerosis Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Medication [Riluzole, Edaravone, Others], Stem Cell Therapy, Others)
  • 5.2.2. By Type (Sporadic ALS, Familial ALS)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
  • 5.2.4. By Company (2023)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Amyotrophic Lateral Sclerosis Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By Type
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Mexico Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Canada Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Distribution Channel

7. Europe Amyotrophic Lateral Sclerosis Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By Type
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By Type
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. South Korea Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Japan Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Distribution Channel

9. South America Amyotrophic Lateral Sclerosis Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By Type
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Amyotrophic Lateral Sclerosis Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment
  • 10.2.2. By Type
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Mitsubishi Tanabe Pharma Corporation
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Biogen Inc.
• 14.3. Brainstorm Cell Therapeutics Ltd.
• 14.4. Amylyx Pharmaceuticals, Inc.
• 14.5. Ionis Pharmaceuticals, Inc.
• 14.6. Sanofi S.A.
• 14.7. Otsuka Pharmaceutical Co., Ltd.
• 14.8. Sun Pharmaceutical Industries Ltd.
• 14.9. Orion Corporation
• 14.10. AB Science

15. Strategic Recommendations

16. About Us & Disclaimer